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Background: Fractional exhaled nitric oxide (FeNO) is useful in predicting treatment 
response in asthma, but it is unknown whether it is a useful baseline measure in patients with 
cough symptoms and previously undiagnosed asthma. 
Aims and objectives: To estimate the interaction between baseline FeNO and treatment 
effect, in terms of cough symptoms, in patients with non-specific respiratory symptoms. 
Methods: This was a multi-centre, randomised controlled trial, where patients in UK and 
Singapore were randomised to receive either extrafine inhaled corticosteroids (ICS, 200 µg 
beclomethasone bid) or placebo for a 4-week period. NIOX VERO (Circassia) was used to 
measure baseline FeNO. The primary endpoint was change in Asthma Control Questionnaire 
score. This work presents the results for a secondary endpoint: change in Visual Analogue 
Scale (VAS) Cough. 
Results: The predominant baseline symptom of the study sample (n=257) was cough, present 
in 85% of patients. We found that higher FeNO was associated with a greater treatment effect. 
For every 10 ppb increase in baseline FeNO, the change in VAS Cough was 3.115 (95% 
confidence interval [CI], 0.579-5.651) greater in the extrafine ICS arm versus placebo. In a 
univariable prediction model of the extrafine ICS arm, patients with baseline FeNO >50 ppb 
were over twice as likely to improve in VAS Cough by ≥20 as patients with FeNO ≤50 ppb 
(unadjusted odds ratio, 2.37 [95% CI, 1.01-5.55]). 
Conclusions: FeNO measurement is a simple, near patient, quantitative and non-invasive 
diagnostic tool for patients with cough symptoms: treatment with ICS may be successful in 
patients found to have high FeNO. Further research is needed to establish cut-points for 
recommendation.   
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